"Elimination of Non-Lipid Enveloped Viruses in the Preparation of a Monoclonal Antibody Purified and Pasteurized Factor VIII Concentrate (Monoclate-P)."

According to an abstract submitted by the authors to the 37th Annual Meeting of the American Society of Hematology, held December 1-5, 1995, in Seattle, Washington, "Viral safety continues to be a focus of attention in the manufacture of replacement factor concentrates used for the control of bleeding in patients with hemophilia A. Recent attention has been focussed on hepatitis A virus (HAY) as a result of outbreaks of infection with this pathogen among European hemophilia A patients treated with solvent/detergent-treated factor VIII concentrates. Other viruses lacking lipid envelopes are also a cause for concern because of their resistance to physicochemical methods of destruction. ...

Want to see the full article?

• Purchase this article for only $3.00